You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 120 Factors associated with extended survival for patients with platinum-resistant ovarian cancer (PROC) treated with modified vaccinia oncolytic virotherapy (VOV)

Article info

Article menu

Download PDFPDF

E-Poster viewings
19–21 September
Basic – Translational science
IGCS19-0687
120 Factors associated with extended survival for patients with platinum-resistant ovarian cancer (PROC) treated with modified vaccinia oncolytic virotherapy (VOV)
Free

Authors

Citation

Manyam M, Stephens A, Kennard J, et al
120 Factors associated with extended survival for patients with platinum-resistant ovarian cancer (PROC) treated with modified vaccinia oncolytic virotherapy (VOV)
International Journal of Gynecologic Cancer 2019;29:A58.

Publication history

  • First published September 18, 2019.
Online issue publication 
September 18, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.